Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Toyota Global Sales Fall as China Demand Slumps 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Add as a preferred source on Google
SEATTLE, April 05, 2018 -- According to Coherent Market Insights, the global disease control and prevention vaccine market was valued US$ 41.12 Billion in 2017 and is projected to exhibit a CAGR of 12.1% over the forecast period (2017 – 2025).
To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/disease-control-and-prevention-vaccine-market-1500
Key Trends and Analysis of the Disease Control and Prevention Vaccine Market:
Increasing research and development activities by manufacturers for introducing new vaccines is expected to drive growth of the market. For instance, in 2014, National Institute of Allergy and Infectious Disease, department of National institute of Health (NIH) collaborating with GlaxoSmithKline developed Ebola vaccine, which is in clinical trial phase in the U.K. Moreover, development of HIV vaccine is major target of vaccine developing companies and institutes, which is expected to be launched over the forecast period, which in turn is expected to drive growth of the disease control and prevention vaccine market. For instance, Johnson & Johnson together with a consortium of global partners initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine. Such novel vaccines launches are expected to boost growth of disease control and prevention vaccines market over the forecast period.
Inovio’s HIV vaccine studies are supported by HIV Vaccine Trails Network (HVTN) and NIH’s National Institute of Allergy and Infectious Disease (NIAID). The studies received financial support of US$ 25 million in 2009, followed by US$ 16 million for five year from NIAID. Furthermore, manufacturers of vaccine market are continuously updating their product portfolio by adopting advance research and development strategies.
Request Sample Copy of this Report
Key Market Takeaways:
- Disease control and prevention vaccine market is projected to witness CAGR of 12.1% during the forecast period (2017–2025), owing to increasing vaccination programs by the government to eradicate disease
- High prevalence of infectious disease is expected to propel demand for infectious disease vaccine in the disease control and prevention vaccine market
- Major players operating in the global disease control and prevention vaccine market include GlaxoSmithKline plc (GSK), Merck & Co. Inc., Sanofi, AstraZeneca PLC, Pfizer, Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Astellas Pharma Inc., and Daiichi Sankyo
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
